



Preferred Drug List (PDL)/Recommended Drug List (RDL)

Policy for Review of Drug Status on the PDL/RDL

- A. All drugs on the PDL/RDL are reviewed at the annual Pharmaceutical and Therapeutics (P & T) Committee Meeting held in the last quarter of the calendar year.
- B. Newly introduced products to the market, with or without submitted supplemental rebate offers, are reviewed by the P & T Committee at the next scheduled quarterly P & T Committee meeting.
- C. Recently introduced drugs that were initially reviewed without a supplemental rebate consideration (see B above), may upon the receipt of a valid supplemental rebate offer be reviewed at the discretion of the P & T Committee at the next quarterly P & T Committee meeting.
- D. All P & T Committee Meetings include an opportunity for Public Comment. All public members, including drug manufacturers, have the opportunity to speak before the P & T Committee about any product. Additionally, Public Comments may be submitted via the website, www.iowamedicaidpdl.com, at all times. These comments are posted to the website and all hardcopies are presented to the P & T Committee at each meeting. It is at the discretion of the P & T Committee to re-discuss drugs mentioned during Public Comment.
- E. Drugs may not be eligible for review if existing contract(s) with other labeler's products precludes additional preferred products within the same therapeutic class on the PDL.
- F. Minutes of the P&T Committee meeting will include the basis on which a drug status recommendation on the PDL/RDL was made.
- G. Manufacturers requesting reconsideration of the status of a product on the PDL/RDL will only be considered if there is new supporting information (i.e. new clinical information or cost data) that impacts the original decision made by the P&T Committee. The request must be submitted by e-mail within five business days following the date of the P & T Committee meeting at which the recommendation was made. The request must be e-mailed to info@iowamedicaidpdl.com.